News for CorMedix Inc. (19KA.F)

Today's Daily Dose brings you news about the regulatory set back of Athenex's oral Paclitaxel and CorMedix's Defencath, ASLAN Pharma's Atopic Dermatitis trial results, FDA panel review of FibroGen's Roxadustat, Morphic Therapeutic's Phase 1 single ascending dose clinical trial of MORF-057, which is in development for the treatment of inflammatory bowel disease, and STRATA Skin's CEO transition.

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.95%

Midway through trading Monday, the Dow traded up 2.09% to 31,580.33 while the NASDAQ rose 2.56% to 13,530.07. The S&P also rose, gaining 2.28% to ...

CRMD stock is headed for the top as excited investors dive in prior to a coming PDUFA date that comes with a high probability of approval.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 3) 9 ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 2) Argenx ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 1) Abbott ...